产品封面图

pMD2.G

收藏
  • ¥800 - 1200
  • Ybscience
  • 中国/美国
  • YB-0887
  • 2025年07月16日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      -20℃

    • 保质期

      6个月

    • 英文名

      pMD2.G

    • 库存

      大量

    • 供应商

      钰博生物

    • 规格

      1ug/5ug

    pMD2.G

    pMD2G载体基本信息

    出品公司: Ybscience
    载体名称: pMD2.G
    质粒类型: 哺乳动物载体;慢病毒包装载体;双质粒包装系统;信封载体
    高拷贝/低拷贝: 高拷贝
    克隆方法: 限制性内切酶,多克隆位点
    启动子: CMV
    载体大小: 5824 BP
    5' 测序引物及序列: CMV fwd 5’CGCAAATGGGCGGTAGGCGTG 3’
    3' 测序引物及序列: --
    载体标签:
    载体抗性: Ampicillin
    筛选标记:
    克隆菌株: DH5α或 HB101
    宿主细胞(系): 包装细胞系如293T
    备注:
    慢病毒包装载体pMD2.G是2质粒包装系统的信封质粒与 psPAX2 一起使用,适用范围、使用方法见下文。

    也可以与第三代包装载体pRSV-RevpMDLg/pRRE一同使用,构成3质粒包装系统。
     
    稳定性: 瞬表达
    组成型/诱导型: 组成型
    病毒/非病毒: 非病毒
     

    pMD2G载体质粒图谱和多克隆位点信息

    pMD2.G载体图谱


     

    pMD2G载体简介

     

    第二代慢病毒包装质粒pMD2.G使用方法-慢病毒包装与转染方法
    
    Day 1
    
    1.      Plate 5 x 105 293T cells in 6 cm2 dishes containing 5 mL of media. (This can be scaled up if desired)
    
    
    Day 2
    
    1.      Set up (use polypropylene tubes for this; polystyrene tubes DO NOT work!):
    
               1 µg retroviral DNA encoding gene X
               1 µg packaging plasmid Mix
                    the packaging plasmid (psPAX2) at a 8:1 ratio with the envelope plasmid (pMD2.G)-a total of 1µg
               DME without serum to 94μL total
               6 μL Fugene
    
           Mix and wait 15 to 30 minutes at room temperature
    
           Add to 293T cells without touching the sides of the dish (DO NOT CHANGE MEDIA)
    
           If you are using amphotropic virus then move immediately to BL2+ in a secondary container, which has an absorbent material. 
    
           (This does not mean a couple of hours; it means Immediately!).  The rest of this protocol is the same for all viruses---the BL2+ safety practices are in place if you are using amphotropic viruses 
    
    
    Day 3
    
    1.      Change the media to whatever media you wish to use when infecting target cells. 293T cells are easily detached so remember not to put the media directly onto to cells, but rather “run” it down the side of the dish. Remember that you will get the highest titer virus when your cells are “happy.”
    
    2.      Plate out your target cells
    
    
    Day 4
    
    1.      Remove the medium from the 293T cells and use a 0.45 u syringe filter to remove any 293T cells. DO NOT use the 0.2 u filter, as it is likely to shear the envelope from your virus
    making it noninfectious
    
            Note: After filtering, the filter should be removed and placed in the biohazard bag in the hood and the syringe rinsed with bleach and decontaminated for a minimum of 20 min. It is useful to place a plastic beaker with bleach in the hood in advance
    
    2.      Add 8 to 10 μg/ml of polybrene (Hexadimethrine bromide) or protamine sulfate to the target cells
    
    3.      Carry out infection for 1 to 4 hours. Remove virus and replace with fresh media
    
            Note: If you wish to do a second infection the following day, it is important to put fresh media on the cells and not let the virus remain on the cells overnight. The media contains huge amounts of envelope, both associated and unassociated with viral particles, which will bind all the cell surface receptors required for virus adsorption, resulting in their down-regulation. Hence, if you don’t change the media after the initial infection, very few receptors will be available for the next round of infection. In addition, very few cells tolerate the presence of high levels of the VSV-G envelope for extended periods of time (i.e. a lot of your cells may die)
    
    
    Day 5 +
    
    1.      Allow the cells to recover and begin to express the virus-encoded genes. The cells usually require 48 hours for this to occur
    
    2.      Add drug if you are scoring for the presence of a vector that carries a drug resistance marker. Prior to this step it is advisable that you titrate the drug to be used for selection in order to know precisely how much to add. In addition, it is necessary to bring an extra plate of uninfected cells (often referred to as “canaries”) which will function as a positive control in the kill assay.  Add drug to both plates. When your canaries are dead, you can remove the drug.
    
    

     

    pMD2G载体序列

    LOCUS       pMD2.G	5824 bp 	DNA	SYN
    DEFINITION  pMD2.G
    ACCESSION   
    KEYWORDS    
    SOURCE      
      ORGANISM  other sequences; artificial sequences; vectors.
    COMMENT     This file is created by Vector NTI
                http://www.biofeng.com/
    COMMENT     VNTAUTHORNAME|biofeng.com|
    FEATURES             Location/Qualifiers
         source          1..5824
                         /organism="pMD2.G"
                         /mol_type="other DNA"
         misc_feature    complement(40..59)
                         /label="SV40pro_F_primer"
         promoter        162..738
                         /label="CMV_immearly_promoter"
         misc_feature    241..528
                         /label="CAG_enhancer"
         misc_feature    695..715
                         /label="CMV_fwd_primer"
         promoter        696..765
                         /label="CMV_promoter"
         promoter        708..827
                         /label="CMV2_promoter"
         misc_feature    739..758
                         /label="pCEP_fwd_primer"
         misc_feature    741..765
                         /label="LNCX_primer"
         misc_feature    1015..1398
                         /label="bGlob_int"
         gene            1450..2973
                         /label="vsv-G"
                         /gene="vsv-G"
         CDS             1450..2985
                         /label="ORF frame 1"
         misc_feature    2950..2982
                         /label="VSVG Tag"
         rep_origin      complement(4055..4674)
                         /label="pBR322_origin"
         gene            complement(4829..5689)
                         /label="Ampicillin"
                         /gene="Ampicillin"
         CDS             complement(4829..5689)
                         /label="ORF frame 1"
         promoter        complement(5731..5759)
                         /label="AmpR_promoter"
    ORIGIN
        1 ggatcccctg agggggcccc catgggctag aggatccggc ctcggcctct gcataaataa
       61 aaaaaattag tcagccatga gcttggccca ttgcatacgt tgtatccata tcataatatg
      121 tacatttata ttggctcatg tccaacatta ccgccatgtt gacattgatt attgactagt
      181 tattaatagt aatcaattac ggggtcatta gttcatagcc catatatgga gttccgcgtt
      241 acataactta cggtaaatgg cccgcctggc tgaccgccca acgacccccg cccattgacg
      301 tcaataatga cgtatgttcc catagtaacg ccaataggga ctttccattg acgtcaatgg
      361 gtggagtatt tacggtaaac tgcccacttg gcagtacatc aagtgtatca tatgccaagt
      421 acgcccccta ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc ccagtacatg
      481 accttatggg actttcctac ttggcagtac atctacgtat tagtcatcgc tattaccatg
      541 gtgatgcggt tttggcagta catcaatggg cgtggatagc ggtttgactc acggggattt
      601 ccaagtctcc accccattga cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac
      661 tttccaaaat gtcgtaacaa ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg
      721 tgggaggtct atataagcag agctcgttta gtgaaccgtc agatcgcctg gagacgccat
      781 ccacgctgtt ttgacctcca tagaagacac cgggaccgat ccagcctccc ctcgaagctt
      841 acatgtggta ccgagctcgg atcctgagaa cttcagggtg agtctatggg acccttgatg
      901 ttttctttcc ccttcttttc tatggttaag ttcatgtcat aggaagggga gaagtaacag
      961 ggtacacata ttgaccaaat cagggtaatt ttgcatttgt aattttaaaa aatgctttct
     1021 tcttttaata tacttttttg tttatcttat ttctaatact ttccctaatc tctttctttc
     1081 agggcaataa tgatacaatg tatcatgcct ctttgcacca ttctaaagaa taacagtgat
     1141 aatttctggg ttaaggcaat agcaatattt ctgcatataa atatttctgc atataaattg
     1201 taactgatgt aagaggtttc atattgctaa tagcagctac aatccagcta ccattctgct
     1261 tttattttat ggttgggata aggctggatt attctgagtc caagctaggc ccttttgcta
     1321 atcatgttca tacctcttat cttcctccca cagctcctgg gcaacgtgct ggtctgtgtg
     1381 ctggcccatc actttggcaa agcacgtgag atctgaattc aacagagatc gatctgtttc
     1441 cttgacacta tgaagtgcct tttgtactta gcctttttat tcattggggt gaattgcaag
     1501 ttcaccatag tttttccaca caaccaaaaa ggaaactgga aaaatgttcc ttctaattac
     1561 cattattgcc cgtcaagctc agatttaaat tggcataatg acttaatagg cacagccata
     1621 caagtcaaaa tgcccaagag tcacaaggct attcaagcag acggttggat gtgtcatgct
     1681 tccaaatggg tcactacttg tgatttccgc tggtatggac cgaagtatat aacacagtcc
     1741 atccgatcct tcactccatc tgtagaacaa tgcaaggaaa gcattgaaca aacgaaacaa
     1801 ggaacttggc tgaatccagg cttccctcct caaagttgtg gatatgcaac tgtgacggat
     1861 gccgaagcag tgattgtcca ggtgactcct caccatgtgc tggttgatga atacacagga
     1921 gaatgggttg attcacagtt catcaacgga aaatgcagca attacatatg ccccactgtc
     1981 cataactcta caacctggca ttctgactat aaggtcaaag ggctatgtga ttctaacctc
     2041 atttccatgg acatcacctt cttctcagag gacggagagc tatcatccct gggaaaggag
     2101 ggcacagggt tcagaagtaa ctactttgct tatgaaactg gaggcaaggc ctgcaaaatg
     2161 caatactgca agcattgggg agtcagactc ccatcaggtg tctggttcga gatggctgat
     2221 aaggatctct ttgctgcagc cagattccct gaatgcccag aagggtcaag tatctctgct
     2281 ccatctcaga cctcagtgga tgtaagtcta attcaggacg ttgagaggat cttggattat
     2341 tccctctgcc aagaaacctg gagcaaaatc agagcgggtc ttccaatctc tccagtggat
     2401 ctcagctatc ttgctcctaa aaacccagga accggtcctg ctttcaccat aatcaatggt
     2461 accctaaaat actttgagac cagatacatc agagtcgata ttgctgctcc aatcctctca
     2521 agaatggtcg gaatgatcag tggaactacc acagaaaggg aactgtggga tgactgggca
     2581 ccatatgaag acgtggaaat tggacccaat ggagttctga ggaccagttc aggatataag
     2641 tttcctttat acatgattgg acatggtatg ttggactccg atcttcatct tagctcaaag
     2701 gctcaggtgt tcgaacatcc tcacattcaa gacgctgctt cgcaacttcc tgatgatgag
     2761 agtttatttt ttggtgatac tgggctatcc aaaaatccaa tcgagcttgt agaaggttgg
     2821 ttcagtagtt ggaaaagctc tattgcctct tttttcttta tcatagggtt aatcattgga
     2881 ctattcttgg ttctccgagt tggtatccat ctttgcatta aattaaagca caccaagaaa
     2941 agacagattt atacagacat agagatgaac cgacttggaa agtaactcaa atcctgcaca
     3001 acagattctt catgtttgga ccaaatcaac ttgtgatacc atgctcaaag aggcctcaat
     3061 tatatttgag tttttaattt ttatggaatt caccccacca gtgcaggctg cctatcagaa
     3121 agtggtggct ggtgtggcta atgccctggc ccacaagttt cactaagctc gcttccttgc
     3181 tgtccaattt ctattaaagg ttccttggtt ccctaagtcc aactactaaa ctgggggata
     3241 ttatgaaggg ccttgagcat ctggattctg cctaataaaa aacatttatt ttcattgcaa
     3301 tgatgtattt aaattatttc tgaatatttt actaaaaagg gaatgtggga ggtcagtgca
     3361 tttaaaacat aaagaaatga agagctagtt caaaccttgg gaaaatacac tatatcttaa
     3421 actccatgaa agaaggtgag gctgcaaaca gctaatgcac attggcaaca gccctgatgc
     3481 ctatgcctta ttcatccctc agaaaaggat tcaagtagag gcttgatttg gaggttaaag
     3541 tttggctatg ctgtatttta cattacttat tgttttagct gtcctcatga atgtcttttc
     3601 actacccatt tgcttatcct gcatctctca gccttgactc cactcagttc tcttgcttag
     3661 agataccacc tttcccctga agtgttcctt ccatgtttta cggcgagatg gtttctcctc
     3721 gcctggccac tcagccttag ttgtctctgt tgtcttatag aggtctactt gaagaaggaa
     3781 aaacaggggg catggtttga ctgtcctgtg agcccttctt ccctgcctcc cccactcaca
     3841 gtgacccgga atccctcgac atggcagtct agcactagtg cggccgcaga tctgcttcct
     3901 cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg agcggtatca gctcactcaa
     3961 aggcggtaat acggttatcc acagaatcag gggataacgc aggaaagaac atgtgagcaa
     4021 aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt gctggcgttt ttccataggc
     4081 tccgcccccc tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga
     4141 caggactata aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc
     4201 cgaccctgcc gcttaccgga tacctgtccg cctttctccc ttcgggaagc gtggcgcttt
     4261 ctcaatgctc acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc aagctgggct
     4321 gtgtgcacga accccccgtt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg
     4381 agtccaaccc ggtaagacac gacttatcgc cactggcagc agccactggt aacaggatta
     4441 gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct
     4501 acactagaag gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa
     4561 gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt
     4621 gcaagcagca gattacgcgc agaaaaaaag gatctcaaga agatcctttg atcttttcta
     4681 cggggtctga cgctcagtgg aacgaaaact cacgttaagg gattttggtc atgagattat
     4741 caaaaaggat cttcacctag atccttttaa attaaaaatg aagttttaaa tcaatctaaa
     4801 gtatatatga gtaaacttgg tctgacagtt accaatgctt aatcagtgag gcacctatct
     4861 cagcgatctg tctatttcgt tcatccatag ttgcctgact ccccgtcgtg tagataacta
     4921 cgatacggga gggcttacca tctggcccca gtgctgcaat gataccgcga gacccacgct
     4981 caccggctcc agatttatca gcaataaacc agccagccgg aagggccgag cgcagaagtg
     5041 gtcctgcaac tttatccgcc tccatccagt ctattaattg ttgccgggaa gctagagtaa
     5101 gtagttcgcc agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt
     5161 cacgctcgtc gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta
     5221 catgatcccc catgttgtgc aaaaaagcgg ttagctcctt cggtcctccg atcgttgtca
     5281 gaagtaagtt ggccgcagtg ttatcactca tggttatggc agcactgcat aattctctta
     5341 ctgtcatgcc atccgtaaga tgcttttctg tgactggtga gtactcaacc aagtcattct
     5401 gagaatagtg tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg
     5461 cgccacatag cagaacttta aaagtgctca tcattggaaa acgttcttcg gggcgaaaac
     5521 tctcaaggat cttaccgctg ttgagatcca gttcgatgta acccactcgt gcacccaact
     5581 gatcttcagc atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa
     5641 atgccgcaaa aaagggaata agggcgacac ggaaatgttg aatactcata ctcttccttt
     5701 ttcaatatta ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat
     5761 gtatttagaa aaataaacaa ataggggttc cgcgcacatt tccccgaaaa gtgccacctg
     5821 acgt

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • 高分辨G带技术

      一、原理 一般常作的G带技术在人类染色体的单倍体中仅能观察到320条带纹,这对于一些染色体细微结构异常的识别是不够的。近年来,用氨甲蝶呤等药物使细胞同步化,另加某些药物如胸腺嘧啶核苷、BrdU等阻止染色体收缩。并用有丝分裂抑制剂秋水仙素或秋水酰胺低浓度短时间处理,结果就能得大量晚前期、前中期和早中期的有丝分裂图象。这样在人类染色体的单倍体带纹数可增加到400条、550条和850条,甚至可达1200~2000条之多。这对于进一步研究较细小的染色体缺陷和基因定位,具有重大意义。二、操作

    • 人可溶性白细胞抗原G(sHLA-G)酶联免疫分析(ELISA)

      人 可溶性白细胞抗原G(sHLA-G) 酶联免疫分析( ELISA ) 试剂盒使用说明书 本试剂仅供研究使用         目的:本试剂盒用于测定人血清,血浆及相关液体样本中可溶性白细胞抗原G(sHLA-G) 含量。 实验原理:     本试剂盒应用双抗体夹心法测定标本中人可溶性白细胞抗原 G(sHLA-G) 水平。用纯化的抗体包被微孔板,制成固相抗体,往包被单抗的微孔中依次加入可溶性白细胞抗原 G(sHLA-G

    • GG-value

      GG-value 物质吸收了单位剂量的放射线时,在放射生物学中为了表示反应的程度所使用的值。用每吸收100eV(电子伏特)的能量所生成或改变的分子数来表示。  

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1200
    上海晶风生物科技有限公司
    2025年11月04日询价
    ¥1
    上海联迈生物工程有限公司
    2026年01月08日询价
    ¥780
    武汉维克赛思科技有限公司
    2026年03月13日询价
    ¥680
    温州科淼生物科技有限公司
    2025年07月11日询价
    询价
    上海北诺生物科技有限公司
    2025年07月12日询价
    pMD2.G
    ¥800 - 1200